{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:37Z","timestamp":1790313517774,"version":"4.1.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Amolyt Pharma, France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Open-label, phase 2 study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12 and C2, n = 16).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Following an optimization period, daily subcutaneous injections of eneboparatide were administered for 3 months at a 20 \u00b5g\/day (C1) or 10 \u00b5g\/day (C2) starting dose. Conventional therapy was progressively removed, and eneboparatide could be titrated up to 60 \u00b5g (C1) or 80 \u00b5g (C2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcomes<\/jats:title>\n                  <jats:p>Proportion of patients achieving independence from conventional therapy, albumin-adjusted serum calcium (ADsCa), 24-h urine calcium (uCa), serum bone turnover markers (serum carboxy-terminal telopeptide of type I collagen and procollagen 1 intact N-terminal propeptide), bone mineral density (BMD), and adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 3 months, \u2265 88% of patients achieved independence from conventional therapy while mean ADsCa was maintained within target range (7.8-9\u2005mg\/dL). Eneboparatide induced a rapid and sustained reduction of mean 24-hour uCa, even among patients with hypercalciuria. Bone turnover markers slightly increased, and BMD remained unchanged, consistent with progressive resumption of physiologic bone turnover. Eneboparatide was well tolerated with no serious AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae121","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:37:01Z","timestamp":1709800621000},"page":"2199-2209","source":"Crossref","is-referenced-by-count":37,"title":["An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-4833","authenticated-orcid":false,"given":"Istvan","family":"Takacs","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Oncology, Semmelweis University , 1088 Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-3877","authenticated-orcid":false,"given":"Emese","family":"Mezosi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Pecsi Tudomanyegyetem , 7623 Pecs , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6983-9320","authenticated-orcid":false,"given":"Alfonso","family":"Soto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario A Coru\u00f1a , 15006 Coru\u00f1a , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[{"name":"Physiologie et Physiopathologie Endocriniennes, AP-HP, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares du M\u00e9tabolisme du Calcium et du Phosphate, Universit\u00e9 Paris-Saclay, Inserm , 94270 Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-2064","authenticated-orcid":false,"given":"Lucile","family":"Figueres","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Clinical Immunology, Centre Hospitalier Universitaire Nantes-Universit\u00e9 de Nantes , 44093 Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-0227","authenticated-orcid":false,"given":"Maria Angeles","family":"Galvez Moreno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Reina Sof\u00eda , 14004 Cordoba , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-2507","authenticated-orcid":false,"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Department of Nephrologie, Hypertension-dialysis, Hospices Civils de Lyon and Claude Bernard University , 69008 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-7840","authenticated-orcid":false,"given":"Francoise","family":"Borson-Chazot","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, Hospices Civils de Lyon and Claude Bernard University , 69394 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-6764","authenticated-orcid":false,"given":"Ismael","family":"Capel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Parc Tauli University Hospital , 08208 Sabadell, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0111-2234","authenticated-orcid":false,"given":"Taha","family":"Ouldrouis","sequence":"additional","affiliation":[{"name":"Amolyt Pharma , 69130 Ecully , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3703-8937","authenticated-orcid":false,"given":"Nad\u00e8ge","family":"Lucas","sequence":"additional","affiliation":[{"name":"Amolyt Pharma , 69130 Ecully , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-7883","authenticated-orcid":false,"given":"Soraya","family":"Allas","sequence":"additional","affiliation":[{"name":"Amolyt Pharma , 69130 Ecully , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2870-0087","authenticated-orcid":false,"given":"Mark","family":"Sumeray","sequence":"additional","affiliation":[{"name":"Amolyt Pharma , 69130 Ecully , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2146-9874","authenticated-orcid":false,"given":"Michel","family":"Ovize","sequence":"additional","affiliation":[{"name":"Amolyt Pharma , 69130 Ecully , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"issue":"18","key":"2024081223513191900_dgae121-B1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2024081223513191900_dgae121-B2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024081223513191900_dgae121-B3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jbmr.3329","article-title":"A population-based study of the epidemiology of chronic hypoparathyroidism","volume":"33","author":"Vadiveloo","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024081223513191900_dgae121-B4","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024081223513191900_dgae121-B5","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024081223513191900_dgae121-B6","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024081223513191900_dgae121-B7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bone.2009.09.020","article-title":"Three dimensional cancellous bone structure in hypoparathyroidism","volume":"46","author":"Rubin","year":"2010","journal-title":"Bone"},{"issue":"1","key":"2024081223513191900_dgae121-B8","first-page":"251","article-title":"Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up","volume":"102","author":"Chawla","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024081223513191900_dgae121-B9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/clinem\/dgab076","article-title":"Vertebral fracture assessment in postmenopausal women with postsurgical hypoparathyroidism","volume":"106","author":"Cipriani","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024081223513191900_dgae121-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-13-1","article-title":"Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density","volume":"13","author":"Mendon\u00e7a","year":"2013","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"2024081223513191900_dgae121-B11","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism\u2013risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024081223513191900_dgae121-B12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/ijem.IJEM_579_19","article-title":"Parathyroid hormone replacement versus oral calcium and active vitamin D supplementation in hypoparathyroidism: a meta-analysis","volume":"24","author":"Palui","year":"2020","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"2024081223513191900_dgae121-B13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ecl.2018.07.010","article-title":"Quality of life in hypoparathyroidism","volume":"47","author":"Vokes","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024081223513191900_dgae121-B14","first-page":"172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024081223513191900_dgae121-B15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000491047","article-title":"A new era for chronic management of hypoparathyroidism: parathyroid hormone peptides","volume":"51","author":"Marcucci","year":"2019","journal-title":"Front Horm Res"},{"issue":"6","key":"2024081223513191900_dgae121-B16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024081223513191900_dgae121-B17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024081223513191900_dgae121-B18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"5","key":"2024081223513191900_dgae121-B19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jbmr.2769","article-title":"Diphtheria toxin- and GFP-based mouse models of acquired hypoparathyroidism and treatment with a long-acting parathyroid hormone analog","volume":"31","author":"Bi","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024081223513191900_dgae121-B20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2024081223513191900_dgae121-B21","volume-title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. Poster #VPP-700","author":"Allas"},{"issue":"5","key":"2024081223513191900_dgae121-B22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4158\/EP15936.OR","article-title":"An open-label extension study of parathyroid hormone RHPTH(1-84) in adults with hypoparathyroidism","volume":"22","author":"Lakatos","year":"2016","journal-title":"Endocr Pract"},{"issue":"11","key":"2024081223513191900_dgae121-B23","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024081223513191900_dgae121-B24","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024081223513191900_dgae121-B25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024081223513191900_dgae121-B26","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD-mineral bone disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2024081223513191900_dgae121-B27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/21548331.2019.1568719","article-title":"Elevated admission serum calcium phosphate product as an independent risk factor for acute kidney injury in hospitalized patients","volume":"47","author":"Thongprayoon","year":"2019","journal-title":"Hosp Pract. (1995)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae121\/56925664\/dgae121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2199\/58769447\/dgae121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2199\/58769447\/dgae121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T01:07:10Z","timestamp":1723511230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/9\/2199\/7623629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,3,6]]},"published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae121","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,6]]}}}